Cargando…

Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis

BACKGROUND: Antifibrotic therapy can slow disease progression (DP) in patients with idiopathic pulmonary fibrosis (IPF). However, the prognostic biomarkers for DP in patients with IPF receiving antifibrotic therapy have not been identified. Therefore, we aimed to evaluate the prognostic efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Myeong Geun, Choi, Sun Mi, Lee, Jae Ha, Kim, Joong-Yub, Song, Jin Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733030/ https://www.ncbi.nlm.nih.gov/pubmed/36494685 http://dx.doi.org/10.1186/s12931-022-02273-6

Ejemplares similares

Krebs von den Lungen‐6 levels in untreated idiopathic pulmonary fibrosis
por: Jiang, Dingyuan, et al.
Publicado: (2022)

Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis
por: Chung, Chiwook, et al.
Publicado: (2022)

Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019
por: Peng, Ding-Hui, et al.
Publicado: (2021)

Krebs von den Lungen 6 decreased in the serum and muscle of GNE myopathy patients
por: Kurashige, Takashi, et al.
Publicado: (2020)

Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis
por: Mostafa, Amira Ismail, et al.
Publicado: (2021)

Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease
por: Ko, Ui Won, et al.
Publicado: (2020)

Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis
por: Shigemura, Masahiko, et al.
Publicado: (2012)

Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
por: Xue, Mingshan, et al.
Publicado: (2021)

Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients
por: D’Agnano, Vito, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
por: Demirdöğen, Ezgi, et al.
Publicado: (2022)

Krebs von den Lungen-6 (KL-6) in cerebrospinal fluid from neurosarcoidosis patients
por: Bocci, Silvia, et al.
Publicado: (2023)

Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients
por: Xue, Mingshan, et al.
Publicado: (2021)

1357. Initial and Peak Serum Levels of Krebs von den Lungen-6 for Prediction of Prognosis in Patients with COVID-19
por: Kim, Geonui, et al.
Publicado: (2023)

Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019
por: Chen, Hao, et al.
Publicado: (2021)

Distribution of Presepsin, Krebs von den Lungen 6, and Surfactant Protein A in Umbilical Cord Blood
por: Nam, Minjeong, et al.
Publicado: (2022)

Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis
por: Nam, Minjeong, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019
por: Yamaya, Takafumi, et al.
Publicado: (2021)

Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality
por: Scarpati, Giuliana, et al.
Publicado: (2022)

Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases
por: Cho, Eun-Jung, et al.
Publicado: (2019)

The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease
por: Zheng, Peiyan, et al.
Publicado: (2021)

Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis
por: He, Jie, et al.
Publicado: (2022)

The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease
por: Ma, Hua, et al.
Publicado: (2020)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis
por: Witarto, Andro Pramana, et al.
Publicado: (2021)

Impact of diabetes and Krebs von den Lungen‐6 on coronavirus disease 2019 severity: A single‐center study from Japan
por: Yakushiji, Yosuke, et al.
Publicado: (2022)

Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality
por: Rai, Meghna, et al.
Publicado: (2023)

Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19
por: Carpio, Carlos, et al.
Publicado: (2023)

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
por: Naderi, Nadereh, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19: A Systematic Review, Meta-Analysis, and Trial Sequence Analysis
por: Shrestha, Abhigan Babu, et al.
Publicado: (2023)

Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis
por: Matuszewski, Michal, et al.
Publicado: (2022)

Evaluation of the clinical performance of the HISCL‐5000 analyzer in the detection of Krebs von den Lungen‐6 antigen and its diagnostic value in interstitial lung disease
por: Wang, Jingxian, et al.
Publicado: (2019)

Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study
por: Castellví, Ivan, et al.
Publicado: (2022)

Histologic Chorioamnionitis, Amniotic Fluid Interleukin 6, Krebs von den Lungen 6, and Transforming Growth Factor β(1) for the Development of Neonatal Bronchopulmonary Dysplasia
por: Matsumura, Hisako, et al.
Publicado: (2017)

Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks
por: Arnold, David T., et al.
Publicado: (2021)

Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis
por: Zhong, Danli, et al.
Publicado: (2020)

Valeur pronostique du KL-6 initial (Krebs von den Lungen 6) au cours de la pneumopathie à SARS-CoV-2
por: Letellier, A., et al.
Publicado: (2022)

Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case–control study
por: Xue, Changjiang, et al.
Publicado: (2017)

Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer
por: Tomita, Masaki, et al.
Publicado: (2017)

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort
por: Cao, Xiao‐yu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vvg76a8b7i9nnorkionnrhkaf6